Private company

Sierra Oncology, Inc.

American pharmaceutical preparations company, incorporated in Delaware1

In its 2022 annual report the company says: “We are a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer. Our main focus is the development and potential commercialization of momelotinib, an investigational agent for the treatment of myelofibrosis.”71 It is headquartered in San Mateo, California.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersSan Mateo, California1
  • Incorporated inDE2
  • Business address1820 Gateway Drive, Suite 110, San Mateo, Ca 944042
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2020

-21647.0%Operating margin3
-26967.3%Net margin3
-82.6%Return on equity3
-$52.4MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2020

  • Research and development100¢$45.1M
  • Income tax0¢$142.0K

Out of $300.0K in revenue.3 The company lost money this year.

Financial statements

Operating income45673-$64.9M in 2020+81% since 2015
-$80.0M-$60.0M-$40.0M-$20.0M02015: -$35.8M-$35.8M20152016: -$48.1M-$48.1M2016+34%2017: -$42.6M-$42.6M2017−11%2018: -$55.4M-$55.4M2018+30%2019: -$67.0M-$67.0M2019+21%2020: -$64.9M-$64.9M2020−3%
Net income45673-$80.9M in 2020+52% since 2015
-$100.0M-$75.0M-$50.0M-$25.0M02015: -$53.3M-$53.3M20152016: -$47.9M-$47.9M2016−10%2017: -$42.0M-$42.0M2017−12%2018: -$53.3M-$53.3M2018+27%2019: -$88.3M-$88.3M2019+66%2020: -$80.9M-$80.9M2020−8%
Fiscal year201520162017201820192020
Revenue$300.0K3
Research and development$26.4M4$33.9M5$30.2M6$41.1M7$53.2M3$45.1M3
Operating expenses
Operating income-$35.8M4-$48.1M5-$42.6M6-$55.4M7-$67.0M3-$64.9M3
Income before tax
Income tax$55.0K4$143.0K5$156.0K6-$302.0K7-$160.0K3$142.0K3
Net income-$53.3M4-$47.9M5-$42.0M6-$53.3M7-$88.3M3-$80.9M3

Compare Sierra Oncology, Inc. with another company

Corporate structure

Sierra Oncology, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Sierra Oncology, Inc.

  • Rock Springs Capital Management LP Filed SC 13G/A on Sierra Oncology, Inc., latest Feb 14, 2023 (2 filings since Feb 15, 2022)
  • Versor Investments LP Filed SC 13G/A on Sierra Oncology, Inc., latest Feb 10, 2023 (2 filings since Apr 22, 2022)
  • Abingworth LLP Filed SC 13D/A on Sierra Oncology, Inc., latest Jul 11, 2022 (4 filings since Nov 5, 2021)
  • Vivo Capital IX, LLC Filed SC 13G/A on Sierra Oncology, Inc., latest Jul 5, 2022 (3 filings since Nov 5, 2021)
  • Longitude Capital Partners III, LLC Filed SC 13D/A on Sierra Oncology, Inc., latest May 6, 2022 (3 filings since Nov 8, 2021)
  • Frazier Life Sciences Public Fund, L.P. Filed SC 13G/A on Sierra Oncology, Inc., latest Mar 29, 2022
  • ORBIMED ADVISORS LLC Filed SC 13D/A on Sierra Oncology, Inc., latest Mar 15, 2022 (3 filings since Nov 5, 2021)
  • CAXTON CORP Filed SC 13G/A on Sierra Oncology, Inc., latest Feb 14, 2022
  • Venrock Healthcare Capital Partners II, L.P. Filed SC 13G/A on Sierra Oncology, Inc., latest Feb 14, 2022
  • New Leaf Biopharma Opportunities I, L.P. Filed SC 13G/A on Sierra Oncology, Inc., latest Feb 11, 2022
  • ADAGE CAPITAL PARTNERS GP, L.L.C. Filed SC 13G/A on Sierra Oncology, Inc., latest Feb 10, 2022
  • PFM Health Sciences, LP Filed SC 13G on Sierra Oncology, Inc., latest Feb 7, 2022
  • Sierra Oncology, Inc. San Mateo, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Sierra Oncology, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$496.0K3 Dec 31, 2021$361.0K3 Dec 31, 2020+37.4%
Accumulated depreciation$355.0K3 Dec 31, 2021$309.0K3 Dec 31, 2020+14.9%
Property and equipment, net$141.0K3 Dec 31, 2021$52.0K3 Dec 31, 2020+171.2%
Operating-lease assets (leased space)$788.0K3 Dec 31, 2021$318.0K3 Dec 31, 2020+147.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$104.7M3 Dec 31, 2021$104.1M3 Dec 31, 2020+0.7%

Leadership

Who has led Sierra Oncology, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Nicholas Glover2015–2020
  2. Stephen George Dilly2020–2022

Chair

  1. Donald R. Parfet2015–2016

President

  1. Nicholas Glover2015–2020
  2. Stephen George Dilly2020–2022

Chief financial officer

  1. Sukhi Jagpal2015–2022
20202025
Board members and other officers (33)

Former names

  • ProNAi Therapeutics IncMay 12, 2004 to Jan 4, 20172

Timeline

  1. Jul 1, 20228-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer45
  2. Jun 29, 20228-K Shareholder vote; Other events46
  3. Jun 22, 20228-K Other events47
  4. Jun 1, 20228-K Other events48
  5. May 6, 20228-K Results of operations49
  6. Apr 13, 20228-K Entered a material agreement; Other events50
  7. Mar 23, 20228-K Executive or director change51
  8. Mar 10, 20228-K Results of operations52
  9. Mar 7, 20228-K Executive or director change53
  10. Jan 27, 20228-K Other events54
  11. Jan 25, 20228-K Entered a material agreement; Results of operations; New debt or obligation55
  12. Nov 5, 20218-K Results of operations; Other events56
  13. Jun 2, 2020New chief executive Stephen George Dilly becomes CEO10
  14. Jul 15, 2015New chief executive Nicholas Glover becomes CEO11

Calendar

When it reported results

  1. May 6, 2022Reported quarterly or annual results49
  2. Mar 10, 2022Reported quarterly or annual results52
  3. Jan 25, 2022Reported quarterly or annual results55
  4. Nov 5, 2021Reported quarterly or annual results56

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

128 filings to the SEC since October 2021: 2 annual reports, 2 quarterly reports, 12 major events, 59 insider forms, 24 large holders, 29 other. The latest 20:

  1. Feb 14, 2023SC 13G/A EDGAR
  2. Feb 10, 2023SC 13G/A EDGAR
  3. Jul 11, 2022SC 13D/A EDGAR
  4. Jul 11, 202215-12G EDGAR
  5. Jul 7, 2022EFFECT EDGAR
  6. Jul 7, 2022EFFECT EDGAR
  7. Jul 5, 2022SC 13G/A AMENDMENT NO. 4 TO SCHEDULE 13G EDGAR
  8. Jul 1, 20224 EDGAR
  9. Jul 1, 202225-NSE EDGAR
  10. Jul 1, 20224 EDGAR
  11. Jul 1, 20224 FORM 4 SUBMISSION EDGAR
  12. Jul 1, 20224 FORM 4 SUBMISSION EDGAR
  13. Jul 1, 20224 FORM 4 SUBMISSION EDGAR
  14. Jul 1, 20224 FORM 4 SUBMISSION EDGAR
  15. Jul 1, 20224 FORM 4 SUBMISSION EDGAR
  16. Jul 1, 20224 FORM 4 SUBMISSION EDGAR
  17. Jul 1, 20224 FORM 4 SUBMISSION EDGAR
  18. Jul 1, 20224 FORM 4 SUBMISSION EDGAR
  19. Jul 1, 20224 FORM 4 SUBMISSION EDGAR
  20. Jul 1, 20224 FORM 4 SUBMISSION EDGAR

The 128 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

18 open-market trades by officers, directors and large owners since October 2021: 8 buys and 10 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 6, 2022Turner William D.Chief Reg & Tech Ops OfficerSale6,347$37.25$236.4KForm 4
Apr 5, 2022Turner William D.Chief Reg & Tech Ops OfficerSale100$37.09$3.7KForm 4
Apr 4, 2022Thomson Mary ChristinaGeneral CounselSale2,000$35.14$70.3KForm 4
Mar 18, 2022Turner William D.Chief Reg & Tech Ops OfficerSale100$37.05$3.7KForm 4
Mar 17, 2022Turner William D.Chief Reg & Tech Ops OfficerSale3,453$37.06$128.0KForm 4
Mar 4, 2022Thomson Mary ChristinaGeneral CounselSale2,000$30.60$61.2KForm 4
Feb 7, 2022Turner William D.Chief Reg & Tech Ops OfficerSale10,000$32.32$323.2KForm 4
Feb 4, 2022Thomson Mary ChristinaGeneral CounselSale2,000$29.78$59.6KForm 4
Feb 2, 2022Tammenoms Bakker Juliet10% ownerBuy175,000$27.00$4.7MForm 4
Feb 2, 2022Richardson JoshuaDirectorBuy175,000$27.00$4.7MForm 4
Jan 31, 2022VIVO VENTURES VII, LLCDirectorBuy800,000$27.00$21.6MForm 4
Jan 31, 2022Aggarwal GauravDirectorBuy800,000$27.00$21.6MForm 4
Jan 31, 2022Sinclair AndrewDirectorBuy150,000$27.00$4.0MForm 4
Jan 31, 2022Abingworth LLP10% ownerBuy150,000$27.00$4.0MForm 4
Jan 26, 2022Thomson Mary ChristinaGeneral CounselSale2,000$29.00$58.0KForm 4
Jan 26, 2022Turner William D.Chief Reg & Tech Ops OfficerSale5,000$27.05$135.2KForm 4
Nov 24, 2021Collard Craig ADirectorBuy7,899$23.09$182.4KForm 4
Nov 23, 2021Collard Craig ADirectorBuy5,601$22.95$128.5KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Sierra Oncology, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSierra Oncology, Inc.1
  • CIK0001290149
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address1820 Gateway Drive, Suite 110, San Mateo, CA 944041
  • Phone(605) 376-86791
  • Shares outstanding24,419,349 as of May 2, 20228
  • Public float$128.4M as of Jun 30, 202170
  • On EDGAR sinceMay 12, 20041
  • Filings527 in all: 4 (184), 8-K (77), 3 (42), SC 13G/A (31), 10-Q (21), SC 13G (19), REGDEX/A (17), SC 13D/A (13)1
    All 43 form types

    424B5 (11), CORRESP (10), DEFA14A (10), S-8 (10), S-8 POS (10), 10-K (7), DEF 14A (7), EFFECT (7), UPLOAD (7), CT ORDER (4), S-3 (4), SC 13D (4), D (3), D/A (3), REGDEX (3), FWP (2), POS AM (2), S-1/A (2), 10-K/A (1), 15-12G (1), 25-NSE (1), 4/A (1), 424B4 (1), 8-A12B (1), CERTNAS (1), DEFM14A (1), DFAN14A (1), DRS (1), DRS/A (1), DRSLTR (1), NO ACT (1), PRE 14A (1), PREM14A (1), S-1 (1), S-3MEF (1)

  • Latest filingsAnnual report (10-K) Mar 10, 2022
    Quarterly report (10-Q) May 6, 2022
    Proxy statement (DEF 14A) Apr 23, 2021
    Latest 8-K (8-K) Jul 1, 2022

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
    SEC EDGAROther events
  48. 48
    SEC EDGAROther events
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
    SEC EDGAROther events
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71